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INTRODUCTION
Inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC) are life-long, immunologically-mediated disorders that are increasing in frequency [1, 2] . One of the main pro-inflammatory cytokines involved in ongoing and uncontrolled inflam mation in IBD is tumor necrosis factor alpha (TNFα). Although the use of antiTNF therapy (Infliximab ® and Adalimumab ® ) has revolutionized the treatment of the disease [3] [4] [5] [6] , one third of patients fail to respond and significant proportion loose sensitivity or become steroid dependent. In the past, serologic and faecal [7] as well as genetic [8, 9] markers have been used to predict response to anti-TNF therapy, however these are often not effective or extremely expensive. Our lack of understanding why certain patients respond to anti-TNF therapy and others don't hinders our progress in predicting which patients are likely to benefit from this costly treatment. Inflammation in IBD is thought to result from inappropriate activation of the innate immune system by intestinal luminal antigens or a defect in its signaling regulation in genetically susceptible individuals [1] . Tolllike receptors (TLR 1-10) are crucial activators of innate immunity. All TLRs signal through MyD88-dependent pathway except TLR3. TLR4 can signal through both MyD88-dependent and MyD88-independent pathways but requires CD14 (Figure 1 ). IRAK4 plays a critical role in initiating nuclear factor kappa B (NFκB) intracellular signalling pathway and therefore production of proinflammatory cytokines. The role of TLRs in IBD is mounting [10] [11] [12] ; polymorphisms in TLR genes are associated with increased risk of IBD [13] [14] [15] and genes regulating TNF signalling and TNF production have been shown to be important predictors of anti-TNF therapy [13] . Together these finding suggest a strong pathogenic association between the TLRs and IBD.
Previously we have demonstrated that measurement of early innate immune function in peripheral blood of children (TLR responses during their first 5 years of life) identified striking differences in the developmental of their innate immune responses and profile of these responses were a good indicator of their subsequent risk of development of allergic disease [16] . As the inflammatory extraintestinal manifestations in UC suggest an immunological component not isolated to the intestine, the same methodology was used to investigate the global innate immune function in UC patients to determine if differences can explain the heterogeneity in their clinical responses to anti-TNF therapy. This study investigated the interaction between the TLR activity in UC patients responsive or nonresponsive to anti-TNF therapy to determine if TLR levels, activity and/or TLR signalling pathways correlate with patient's response to anti-TNF therapy. It was hypothesised that there are inherent differences in innate immune function between responders and nonresponders which may explain differences in their clinical effectiveness of treatment. These novel results extend our understanding of intestinal inflammation pathogenesis and implications of innate immunity in UC patients' response to anti-TNF therapy.
MATERIALS AND METHODS

Study design
This study was conducted as a prospective and retrospective observational study. The former, to determine whether inflammation levels, medication use, patient demographics, surgery and anti-TNF therapy itself influenced patient outcome (response or non-response to TNF therapy), and the latter to determine if there were differences in the underlying mechanisms responsible for TLR recognition and innate immune response. To address these aims, proinflammatory cytokine levels, TLR expression, TLR signalling and cell populations were analysed from isolated PBMCs pre-and post-anti-TNF therapy and; (1) correlated back to inflammation levels, medication use, patient demographics, surgery and anti-TNF therapy itself, and (2) were then compared between responders and non-responders.
Participants
IBD patients (n = 42) and healthy controls (n = 12) were recruited from Centre for Inflammatory
9106
November 7, 2016|Volume 22|Issue 41| WJG|www.wjgnet.com Table  1 ). Isotype-matched antibodies were used as controls (Supplement Table 1 ) and assessed by FACS analysis. For the analysis of TLR and CD14 receptor levels, unstimulated and stimulated PBMCs were stained with TLR2 (1:20 dilution, PE; eBiosciences, San Diego, CA, United States), TLR4 (1:50 dilution, APC; eBiosciences), TLR9 (1:20 dilution, APC; BD Pharmingen, San Diego, CA, United States) and CD14 (1:20 dilution, FITC; eBiosciences) prior to fixing according to manufacturer's instructions. Isotype-matched antibodies were used as controls.
To address differences in MyD88-dependent signalling in unstimulated and stimulated PBMCs, PBMCs were cultured alone or with TLR2, TLR3, TLR4, TLR7 TLR9 agonists as previously described for 15 min at 37 ℃ with 5% CO2. Cells were fixed and permeabilized according to manufacturer's instructions (BD Biosciences, San Diego, CA, United States) and stained for phosphorylated NFκB (pNFκB) (1:5 dilution, AF488; BD Biosciences), total IRAK4 (1:5 dilution, PE; BD Biosciences) and total Iκβα (1:5 dilution, AF647; BD Biosciences). Stained cells were captured using the FACScanto II bench top flow cytometer (BD Biosciences) at the CMCA, UWA, Australia and analysed using FlowJO v7.6.3 research software (Tree Star Inc. Oregon, United States).
Statistical analysis
Significance between groups at 95% confidence level was determined by paired and Mann-Whitney nonparametric unpaired t tests, using Graphpad Prism 4.0 software package (Graphpad, San Diego, CA, United States). Results were expressed as median geometric mean with 95% confidence interval, foldchange from basal ± SD, mean percentage of total cell population ± SD or mean fluorescence intensity (MFI) ± SD. Correlation between medications and patient' s response to anti-TNF therapy was determined by multiple regression analyses using SPSS version 14.0 software package for Windows PC (IBM, Armonk, NY, United States). Statistical significance was considered as P < 0.05. Bowel Diseases, Fremantle Hospital, Perth, Australia. The diagnosis of CD and UC was made based upon clinical, endoscopic, histopathological and radiological findings, and classified by the "Montreal classification". Patient demographic data included data of birth, age at diagnosis, age at time of study, timing of anti-TNF therapy, concurrent immunosuppressive medications, surgeries, family and smoking history. To examine the effects of disease, anti-TNF therapy, inflammation and medication use on innate immunity, blood was taken from 18 IBD patients (13 with CD and 5 with UC) prior (pre-anti-TNF) and 3 mo after anti-TNF therapy commenced (post-anti-TNF). To study immune responses in responder and non-responder UC patients, blood was collected from separate 24 UC patients and compared to 12 healthy controls. UC patients achieving clinical remission, defined by a Colitis Activity Index (CAI) ≤ 4, and normal C reactive protein (CRP) ≤ 10 mg/L, were considered responders (Rs, n = 12), whilst those who failed to respond with a reduction in CAI of < 4 points and a consistently elevated CRP as non-responders (NRs, n = 12).
Blood collections and processing
Sixty millilitres of peripheral blood was collected and peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque gradient centrifugation and cryopreserved (7.5% DMSO) at -80 ℃ for future use.
PBMC stimulation
PBMCs were cultured alone or with various TLR agonists including lipoteichoic acid (LTA 1 µg/mL, TLR2 ligand), Poly I:C (50 µg/mL, TLR3 ligand), E. coli lipopolysaccharide (LPS 10 ng/mL, TLR4 ligand), Flagellin (1 µg/mL, TLR5 ligand), Imiquimod (10 µg/mL, TLR7 ligand), Gardiquimod (10 µg/mL, TLR8 ligand) or CpG oligonucleotide (CpG 3 µg/mL, TLR9 ligand); all purchased from InvivoGen, CA, United States. All cultures were plated in duplicate in 96-well roundbottom plates in 250 µL RPMI (Gibco, Life Technology, Grand Island, NY, United States) supplemented with 10% foetal calf serum (Australia Biosearch, Australia) and incubated at 37 ℃ with 5% CO2 for 24 h (LTA, Poly I: C, LPS and Flagellin) or 48 h (Imiquimod, Gardiquimod or CpG). The supernatants were then removed and stored at -20 ℃ until cytokine analysis.
Multiplex bead assay
Cytokines [TNFα, interferon γ (IFNγ), interleukin (IL)-1β, IL-6, IL-9, IL-10, IL-12, IL-13 and IL-17A] were measured from culture supernatants. Multiplex beads for the BioPlex ® multiplex system (Life Sciences,
Bio-Rad Laboratories Pty, Ltd., Vic, Australia) were diluted 1:2 in bead diluents and the 9plex bead assay according to the manufacturer's protocol using a Luminex 
RESULTS
Baseline inflammation, medication use and disease type in UC patients prior to anti-TNF therapy
Clinical data comparison of patient population:
To determine if innate immune response were altered by the use of immuno-suppressants and antiinflammatory medications, disease type or the level of inflammation measured by erythrocyte sedimentation rate (ESR), Creactive protein (CRP) levels, CD activity index (CDAI) and partial Mayo score preantiTNF therapy, the clinical data of 18 IBD patients were compared (Tables 1 and 2 ). Prior to anti-TNF therapy, clinical data of responders and non-responders demonstrated no significant differences in the number of patients on individual or combined immunesuppressants, methotrexate, 5ASA or corticosteroids (Table 2) . Although the ESR and CRP levels appeared higher in responders, they were not significantly different to non-responders suggesting similar level of disease severity/activity between the two groups. This suggests that whether a patient responds or not to anti-TNF therapy is not predicted by their ESR, CRP, CDAI or partial Mayo score, nor their medication use. As expected, the partial Mayo scores were significantly higher in nonresponders (7.3 ± 0.6, n = 3) than in responders (0.5 ± 0.5, n = 4) postanti TNF therapy (P = 0.004), as were the CDAI scores (198 ± 42, n = 2 vs 80.1 ± 21.7, n = 9 respectively, P = 0.04). This was also true of the CRP levels (23 ± 1.9, n = 5 vs 7.4 ± 3.4, n = 13 respectively, P = 0.01) (data not shown). Considering CD and UC patients separately, all patients suffered from moderatelysevere inflammation and there were no significant differences in medications, ESR or CRP levels pre anti TNF therapy (Table 3) . At the time of the second blood draw (3 mo post-anti-TNF induction therapy), two thirds of the patients had gone into remission with anti-TNF therapy (CDAI < 150, CAI ≤ 4 and CRP ≤ 10 mg/L) and had ceased steroid therapy. Five (n = 5) did not respond to anti-TNF therapy, three (n = 3) continued on steroid therapy (1 responder and 2 nonresponders P > 0.05) and two (n = 2) underwent surgery with cessation of immunomodulation.
Basal and stimulated PBMC cytokine production pre-and post-anti-TNF therapy: To investigate whether medication use, anti-TNF therapy, disease type or inflammation affected baseline PBMC function, isolated PBMCs were cultured in vitro and basal and stimulated supernatant cytokine levels measured. Basal innate (TNF, IL-1β, IL-6), immunoregulatory (IL-10), Th1 (IL-12 and IFNγ) and Th2 (IL-9, IL-13 and IL17A) cytokine expression was similar pre and post anti-TNF therapy suggesting it was not affected by treatment (Supplementary Figure 1) . To determine if anti-TNF therapy affected the PBMC's ability to recognise and respond to stimulation, TNF production pre-and post-anti-TNF therapy was measured post TLR activation. TNF production was unaffected or even higher (P = 0.03 for TLR4 stimulation) post-TNF therapy compared to production pre-therapy (Supplementary Figure 2) suggesting that anti-TNF therapy does not reduce the PBMC's ability to recognise, or responds to TLR activation. None of the other cytokine levels were affected post therapy (data not shown). TNF production post TLR3 and TLR4 activation was approximately 10fold higher than stimulation of other TLRs.
The immune response of UC responders and nonresponders to anti-TNF therapy
As the use of anti-TNF therapy for the treatment of UC is associated with higher rates of primary and secondary non-responses than in CD patients, we next set out to study innate immune responses in UC patients who respond or do not respond to treatment.
Demographic and clinical data comparison of UC patient cohort: PBMCs from 24 UC patients (n = 12 responders and n = 12 non-responders to anti-TNF therapy), and 12 healthy controls were isolated. Bloods were taken post-anti-TNF therapy, with the median time being 208 (12468) wk for responders and 156 (12364) wk for nonresponders (P = 0.52). No significant demographic differences were detected between the UC populations except that responders had longer disease duration (P = 0.01) ( Table 4) . None of the controls were on any medications or suffering from any infections or inflammatory conditions. There was no correlation between any of the medications (alone or in combination) and patient's response to anti-TNF therapy. At time of blood draw (post-anti-TNF therapy) all responders were in clinical remission (CAI ≤ 4 and CRP ≤ 10 mg/L) with 5 patients on maintenance antiTNF therapy, 8 on thiopurine and 4 on 5-ASA. Of the non-responders, 3 had blood drawn following recovery from colectomy from uncontrolled UC, 1 was in remission on tacrolimus and 4 had ongoing inflammation with 6 taking oral corticosteroids and all receiving thiopurines (Table 5) .
Basal cytokine production in UC responders and non-responders: PBMCs from UC patients (responders and non-responders) had significantly greater basal IL-1β, IL-6 and IL-10 levels compared to healthy controls (Figure 2 ). Non-responders had significantly increased TNF, IL1β and IL-10 compared to responders. There were no differences in basal IL-12 production between UC groups compared to controls or production of any of the Th2 cytokines measured (IL-5, IL-9, IL-13 or IL-17A) (Figure 2 ). The Th1 cytokine IFNγ was significantly elevated in nonresponders compared to responders and controls (Figure 2 ).
Differences in stimulated cytokine production by UC responders and non-responders: In general, responders had similar TNF, IL-1β, IL-6 and IL-10 responses to healthy controls following TLR stimulation; exceptions being increased TLR9induced TNF in responders ( Figure 3A) , and reduced TLR7-induced IL-1β ( Figure 3B ) as well as reduced TLR-3, -5 and -7 induced IL-6 responses (P = 0.04) ( Figure  3C ). In contrast, TNF, IL-1β, IL-6 and IL-10 responses 
to all TLR agonists were significantly lower in nonresponders compared to healthy controls (P < 0.01) ( Figure 3A-D) . Non-responders had significantly lower TNF and IL-1β production to all TLRs compared to responders ( Figure 3A and B) as well as reduced TLR9-induced IL-6 ( Figure 3C ) and TLR3, 4, 8 and -9-induced IL-10 ( Figure 3D ).
PBMC characterisation
Isolated PBMCs are a mixed cell population and differences in cytokine production are likely to be attributed to differences in distribution of cellular populations. Characterization of cellular populations in the three study groups have shown both UC subgroups to have higher percentage of monocytes in circulating blood compared to controls ( Figure 4A ). Non-responders had a significantly lower plasmacytoid DC (pDC) frequency compared to responders and controls (P < 0.01). This decrease in pDCs was associated with increased percentage of CD4 + regulatory T cell (Tregs) compared to controls (P = 0.03) ( Figure 4A ). Increased Tregs was of borderline significance in responders compared to controls (P = 0.09; Figure 4A ). We found no difference in memory, naïve, CD4 between the groups (data not shown).
PBMC expression of TLR2, -4, -7, -9 and CD14
As pDC frequency varied between responders and non-responders, the level of basal and stimulated TLR2, TLR4, TLR7, TLR9 and CD14 expression levels were assessed. The baseline expression of TLRs and CD14 were similar between the three groups and was increased to similar levels in each of the groups following stimulation ( Figure 4B ). No differences were observed in basal or stimulated TLR/CD14 expression levels between the groups suggesting that the percentage pDC did not impact expression of TLRs or CD14.
TLR signalling
MyD88-dependent signalling was assessed following TLR2, 3, 4, 7 and 9 stimulation of PBMCs by measuring total IRAK4, total Iκβα and phosphorylated NFκB (pNFκB) activity. TLR-3 was used as a control as TLR3-mediated signalling is independent of MyD88, IRAK4 and IRAK1 [17] . Total IRAK4 levels did not change upon TLR-3 activation and no differences in protein levels between the 3 groups were identified (data not shown). When comparing basal to stimulated total IRAK4 levels; responders and controls had similar response profiles, that is, significantly lower total IRAK4 levels upon TLR stimulation ( Figure 5 ), whilst nonresponders failed to reduce total IRAK4 following TLR2, 4, and 7 stimulation ( Figure 5 ). Total IRAK4 was significantly increased in nonresponders following TLR-9 activation compared to basal levels (P = 0.03, Figure 5 ). This suggests that in the nonresponders, the degradation/inhibition of IRAK4 may be dysregulated resulting in its aberrant accumulation. Whilst total Iκβα were significantly decreased in all groups following stimulation (P < 0.02 for all), pNFκB were significantly increased in all groups (P < 0.02 for all; Figure 5 ). 
DISCUSSION
Non-communicable disease including cardiovascular, metabolic, IBD and allergic diseases are now surpassing infectious disease accounting for more than 60% of all global deaths [18] . As there were no significant differences in medication use, baseline ESR, CRP and inflammation levels (as indicated by partial Mayo scores and CDAIs) between responders and non-responders prior to anti-TNF induction (part 1 of study), this strengthens the hypothesis that the differences are intrinsic and that there is an inherent difference within the innate immune response of these two cohorts, i.e., their PBMCs function differently in response to TLR stimulation. This was clearly demonstrated in nonresponders having significantly higher basal Th1 cytokine production compared to responders. Having higher Th1 but not Th2 cytokine production was also an indicator that the problem lays within the innate and not the adaptive immune response. By using both UC and CD patients in the initial experiments, it demonstrated that these intrinsic differences may be inherent in both UC and CD patients, and the ability to be able to target and treat patients based on their innate immune response may be applied to both of the IBD cohorts.
When specifically looking at differences between the UC responders and non-responders, it was noted that the non-responders had a significantly higher constitutive or basal cytokine production than responders and controls, and smaller fold change in cytokine production upon TLR stimulation. High basal cytokine levels and the lack of fluctuation in cytokine production upon TLR stimulation suggests that the mechanisms involved in the negative regulation of TLR signalling may be impaired. Indeed, low levels of immunoregulatory cytokine IL-10 seen in nonresponders compared to responders following TLR activation (Figure 3 ) may explain why inflammation cannot be controlled with anti-TNF therapy in these patients.
We demonstrated that non-responders had a significantly lower number of pDCs in their peripheral blood compared to responders and to healthy controls. Others have shown that UC and CD patients experience a significant drop in their peripheral pDC populations during acute inflammation and significant increase in numbers within the intestinal mucosa [19] . The decreased pDC frequency we see in non-responders may result from continuous migration of peripheral pDCs into the intestinal mucosa whereupon they mature, activate and contribute to gut inflammation, thus resulting in an elevated basal Th1 cytokine profile which is characteristic of this population. The maturational status of the peripheral pDCs in non-responders may also be of importance, as healthy individuals display an immature pDC phenotype which normally induces T cell unresponsiveness [20] , whilst IBD patients have a lack of immature peripheral pDCs which would perpetuate inflammation [21] . Further investigation into the distribution of pDCs in the peripheral blood and the intestinal mucosa, and their maturational status in the UC subgroups is required. The increased frequency of CD4 + Treg cells in non-responders could suggest a problem with Treg homing to the mesenteric lymph nodes and lamina propria to inhibit pathogenic T effector cells during inflammation via direct contact with cD11c + dendritic cells [22] , thus leading to ongoing inflammation. Consistent with the increase in proinflammatory cytokines, monocyte frequency was significantly greater in both UC subgroups compared to controls, and no differences were observed in naïve, memory or CD8 + effector or CD8 + Treg cell frequency, which again supports the concept that the differences in immunologic responses between the UC subgroups lie within the innate immune system. Downstream of the TLRs, we saw accumulation of total IRAK4 in nonresponders upon stimulation, particularly following TLR9 activation. IRAK4 is a key signalling component in the innate immune response [23] and IRAK4 deficiencies have been implicated in IBD [24] . We know that IBD patients who do not respond to antiTNF therapy maintain an increased expression of pro-inflammatory cytokines [25] . In our non-responder population, this is associated with IRAK4 accumulation and we may speculate such accumulation may lead to prolonged activation of the signalling pathway resulting in sustained and excessive proinflammatory cytokine production seen in UC patients. Our signalling data shows nonresponders to have normal IRAK4 kinase activity however, other mechanisms which may contribute to its accumulation such as defects in IRAK4 degradation or inhibition remains to be tested. It's been previously shown that IL10 can induce IRAK4 ubiquitination and proteasomal degradation [26, 27] . Our results support reduced ability of non-responders to induce IRAK4 ubiquitination due to their reduced capacity to produce IL-10 following TLR stimulation. Alternatively, IRAK4 activity is inhibited by cleavage into its inactive form [26] . Cleavage occurs by an NFκB-induced protease resulting in a smaller molecular weight protein (32 kDa) that can also be recognised by antiIRAK4 antibodies [26] . As IRAK1 phosphorylation and NFκB activation precedes IRAK4 cleavage, this suggests that this may be part of a negative feedback inhibition loop [26] . There is no doubt that anti-TNF therapy can be effective in UC but only in some patients. The ability to predict patient's response to anti-TNF therapy would allow for more targeted therapy with better cost-effectiveness. Here we provide evidence which suggests that heterogeneity in the innate immune function between UC patients may give us an important insight into their subsequent responses to future anti-TNF therapy. This would be particularly beneficial for the patient with acute severe colitis requiring rescue therapy when a choice must be made between cyclosporine or anti-TNF therapy. It is important to acknowledge that one of the potential limitations of this study is the relatively small and a mixed population of patients (CD and UC) used. Moreover, it is known that pathogenesis of CD and UC are different and disease can be more severe in the elderly [28] . In our cohort, results could not be explained by differences in age between groups and our functional innate differences between responders and non-responders have been performed in UC patients only. Our data offers promise for serological measure of innate immune function in UC patients as a potential application in clinic to predict response to costly anti-TNF therapy. These data remain to be confirmed in a larger cohort of not only UC but also CD patients. With better prediction of the response to therapy, targeted patient treatment may be possible in the future, resulting in improved efficacy and costeffectiveness of treatment for all IBD patients. consent and blood for this study, and Frances Lloyd for the isolation of PBMCs.
COMMENTS
Background
Monoclonal antibodies against tumour necrosis factor [anti-tumour necrosis factor (TNF) therapy] can be used to treat patients with ulcerative colitis (UC) who are no longer responding to corticosteroids. Anti-TNF treatment is expensive and 30%-40% of patients do not respond.
Research frontiers
Unravelling the mechanisms involved in lack of response to anti-TNF is paramount for prediction of response to treatment.
Innovations and breakthroughs
Here the authors show, for the first time, that differences in innate immune function exist between UC patients who respond to anti-TNF therapy and those that don't. Both quantitative (difference in presence of inflammatory cells in their peripheral blood) and qualitative (production of cytokines and signalling capacity following activation of innate immune pathways) differences exist between responders and non-responders.
Applications
Measurement of innate immune function in the blood of UC patients (their response to TLR agonists) may be a useful tool in predicting patient's response to anti-TNF treatment. With improved prediction of the response to therapy, targeted and individualised patient treatment may be possible in future, resulting in improved efficacy and cost-effectiveness.
Terminology
Innate immune function is measured by cellular response to toll-like receptor (TLR) stimulation. To understand which TLRs are implicated in lack of response to anti-TNF treatment, we examined peripheral blood mononuclear cells responses to a wide range of TLR agonists and closely examined the TLR signalling pathway molecules.
Peer-review
In the presented article the authors aimed to predict anti-TNF response in IBD patients by means of alterations in immune functions. There are two parts of the study. The effects of disease, treatment and inflammation on innate immunity were evaluated in 18 patients. In the second part, the differences between responders and non-responders were evaluated in 24 patients. The study adds new knowledge to the current literature.
